Can Ebru Kurt

Geboren in Ankara. Mittlere Schulbildung am Privatgymnasium Tevfik Fikret in Ankara. Das Medizinstudium an der Medizinischen Fakultät der Universität Hacettepe 2006 abgeschlossen, nachdem im Rahmen des Erasmus-Programms auch in zwei verschiedenen Krankenhäusern in Frankreich gearbeitet worden war. Im selben Jahr Beginn der Facharztausbildung in Neurologie an der Abteilung für Neurologie der Medizinischen Fakultät der Universität Hacettepe. Für die Dissertation mit dem Titel „RAGE- und NF-kappa-B-Aktivierung bei vaskulitischen Neuropathien und nichtentzündlichen axonalen Neuropathien“ Gewinn des „Preises für junge Forschende auf dem Gebiet der Neuropathie“ der Europäischen Neurologischen Gesellschaft. 2011 mit einem Stipendium der Europäischen Neurologischen Gesellschaft an der Universität Würzburg (Deutschland) Fortsetzung der Arbeiten zu Neuropathien unter Leitung von Prof. Dr. Claudia Sommer, ausgewiesen auf dem Gebiet neuropathischer Schmerzen und Neuropathien. 2012 Abschluss der Facharztausbildung in Neurologie, anschließend staatlicher Pflichtdienst am Staatskrankenhaus Anamur. 2014–2016 Masterabschluss in Neuroimmunologie an der Abteilung für Klinische Neurologische Wissenschaften des Instituts für Neurologische Wissenschaften und Psychiatrie der Universität Hacettepe. 2015 Beginn der Tätigkeit als Assistenzprofessur an der Abteilung für Neurologie der Universität Hacettepe. 2017 Titel „Assoz. Prof. für Neurologie“. 2021–2022 Mitwirkung an klinischen und Laborarbeiten zu Gentherapien bei neuromuskulären Erkrankungen mit Prof. Dr. Jerry Mendell (Entwicklung von Gentherapien bei Spinaler Muskelatrophie (SMA) und Duchenne-Muskeldystrophie) am „Nationwide Children’s Hospital“ (Ohio, Vereinigte Staaten von Amerika). 2023 Titel „Prof. für Neurologie“. Fortsetzung der Arbeiten zu genetischen Erkrankungen im Rahmen der laufenden Promotion an der Abteilung für Medizinische Biologie. Vorstandsmitglied der Arbeitsgruppe für Neuromuskuläre Erkrankungen und Neuropathische Schmerzen der Türkischen Neurologischen Gesellschaft. Neben den klinischen Arbeiten im Bereich klinischer neuromuskulärer Erkrankungen an der Abteilung für Neurologie Durchführung und pathologische Auswertung diagnostischer Muskel-, Nerven-, Muskel-Nerven- und Hautbiopsien im Forschungslabor für Neuromuskuläre Erkrankungen der Abteilung. Gute Englisch- und Französischkenntnisse.

1. Case Report: Steroid Responsive Pompe Like Inflammatory Myositis With Complete Recovery After Allogeneic HSCTKART BAYRAM G. S., FIRLATAN YAZGAN B., ALADAĞ KARAKULAK E., Bekircan-Kurt C. E., AKDOĞAN A.International Journal of Rheumatic Diseases, cilt.29, sa.4, 2026 (SCI-Expanded, Scopus)
2. Increased epidermal growth factor expression in amyotrophic lateral sclerosis patients: A potential protective mechanism against pressure ulcersARSLAN D., KURT E., ERGÜL ÜLGER Z., ERDEM ÖZDAMAR S., Tan E., Bekircan-Kurt C. E.Turk Noroloji Dergisi, cilt.32, sa.3, ss.230-236, 2026 (ESCI, Scopus)
3. Detection of inflammation and glial cell-related biomarkers in adults with spinal muscular atrophy receiving nusinersen therapyArslan D., ERGÜL ÜLGER Z., Goksen S., Inan B., ESENDAĞLI G., ERDEM ÖZDAMAR S., et al.Neurological Sciences, cilt.47, sa.1, 2026 (SCI-Expanded, Scopus)
4. Random X chromosome inactivation in female Charcot-Marie-Tooth disease type X1: insights from sural nerve biopsy analysisKURT C. E., Aksu-Menges E., Kumtepe E. T., DURMAZ ÖZDİNÇ C. D., Terzi Y. K., ERGÜL ÜLGER Z., et al.BMC NEUROLOGY, cilt.25, sa.1, 2025 (SCI-Expanded, Scopus)
5. Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanomaInan B., Duzgun U., ERGÜL ÜLGER Z., KURT C. E., Ceylan B. N., Karadas O., et al.ANTI-CANCER DRUGS, cilt.36, sa.7, 2025 (SCI-Expanded, Scopus)
6. Transitioning From Nusinersen to Risdiplam for Spinal Muscular Atrophy in Clinical Practice: A Single-Center ExperienceKURT C. E., Subramanian S., Chagat S., Mackenzie S. J., Iammarino M., Reash N., et al.MUSCLE & NERVE, cilt.71, sa.3, ss.414-421, 2025 (SCI-Expanded, Scopus)
7. Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravisİNAN B., ORHAN İ. G., KURT C. E., ERDEM ÖZDAMAR S., Tan E.IRISH JOURNAL OF MEDICAL SCIENCE, cilt.193, ss.2989-2994, 2024 (SCI-Expanded, Scopus)
8. A novel pathogenic PTRH2 variant indicates seizure association with protein-truncating variants in Infantile-Onset Multisystem Neurologic, Endocrine and Pancreatic Disease (IMNEPD)AKÇİN Ö. Ç., KURTÇU O., DERİCİOĞLU N., ERDEM ÖZDAMAR S., KURT C. E., ALTINER Ş., et al.EUROPEAN JOURNAL OF HUMAN GENETICS, ss.1494, 2024 (SCI-Expanded, Scopus)
9. Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia GravisARSLAN D., ERGÜL ÜLGER Z., Goksen S., ESENDAĞLI G., ERDEM ÖZDAMAR S., Tan E., et al.EUROPEAN NEUROLOGY, cilt.87, sa.5-6, ss.223-229, 2024 (SCI-Expanded, Scopus)
10. A novel pathogenic PTRH2 variant indicates seizure association with protein-truncating variants in Infantile-Onset Multisystem Neurologic, Endocrine and Pancreatic Disease (IMNEPD)AKÇİN Ö. Ç., KURTÇU O., DERİCİOĞLU N., ERDEM ÖZDAMAR S., KURT C. E., ALTINER Ş., et al.EUROPEAN JOURNAL OF HUMAN GENETICS, ss.1494, 2024 (SCI-Expanded, Scopus)
11. Differentiating recurrent Guillain-Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature reviewİNAN B., KURT C. E., Demirci M., ERDEM ÖZDAMAR S., Tan E.ACTA NEUROLOGICA BELGICA, cilt.124, ss.1467-1475, 2024 (SCI-Expanded, Scopus)
12. VARIABLE PHENOTYPE IN FEMALES WITH HETEROZYGOUS GJB1 MUTATIONKURT C. E., ERGÜL ÜLGER Z., TEMUÇİN Ç. M., Kumtepe E. T., BALCI B., Tan E., et al.JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2024 (SCI-Expanded, Scopus)
13. Recurrent simultaneous central nervous system demyelination with possible peripheral demyelination / nodopathy in a seronegative patientİNAN B., KURT C. E., YILDIZ SARIKAYA F. G., GÖÇMEN R., TEMUÇİN Ç. M., Tuncer A., et al.IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE, cilt.77, sa.9-10, ss.357-360, 2024 (SCI-Expanded, Scopus)
14. Nusinersen for adults with spinal muscular atrophyARSLAN D., İNAN B., KILINÇ M., Bekircan-Kurt C. E., ERDEM ÖZDAMAR S., Tan E.Neurological Sciences, cilt.44, sa.7, ss.2393-2400, 2023 (SCI-Expanded, Scopus)
15. The evaluation of small fibers in multiple sclerosisBekircan-Kurt C. E., Jahanroshan J., Tuncer A., ERGÜL ÜLGER Z., Gunes G., ERDEM ÖZDAMAR S., et al.Multiple Sclerosis and Related Disorders, cilt.72, 2023 (SCI-Expanded, Scopus)
16. Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALSAKSU MENGEŞ E., Balci-Hayta B., Bekircan-Kurt C. E., Aydinoglu A. T., ERDEM ÖZDAMAR S., Tan E.ACTA NEUROLOGICA BELGICA, cilt.122, sa.6, ss.1499-1509, 2022 (SCI-Expanded, Scopus)
17. Comprehensive evaluation of velopharyngeal function in myasthenia gravis patientsBAŞTUĞ DUMBAK A., KULAK KAYIKCI M. E., ŞAHİN M. İ., KUŞCU O., Bekircan-Kurt C. E., ERDEM ÖZDAMAR S.ACTA NEUROLOGICA BELGICA, cilt.122, sa.5, ss.1229-1236, 2022 (SCI-Expanded, Scopus)
18. Identifying a Cut-off Point for Timed Up and Go Test in Neuromuscular DiseasesDemirci C. S., SÜTÇÜ G., AYVAT F., ONURSAL KILINÇ Ö., DOĞAN M., AYVAT E., et al.TURKISH JOURNAL OF NEUROLOGY, cilt.28, sa.1, ss.6-9, 2022 (ESCI, Scopus, TRDizin)
19. The functional and structural evaluation of small fibers in asymptomatic carriers of TTR p.Val50Met (Val30Met) mutationBekircan-Kurt C. E., YILMAZ E., ARSLAN D., Yildiz F. G., DİKMETAŞ Ö., ERGÜL ÜLGER Z., et al.NEUROMUSCULAR DISORDERS, cilt.32, sa.1, ss.50-56, 2022 (SCI-Expanded, Scopus)
20. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension studySiddiqi Z. A., Nowak R. J., Mozaffar T., O'Brien F., Yountz M., Patti F., et al.Muscle and Nerve, cilt.64, sa.6, ss.662-669, 2021 (SCI-Expanded, Scopus)
21. One Disease with two Faces: Semidominant Inheritance of a Novel HTRA1 Mutation in a Consanguineous FamilyBekircan-Kurt C. E., ÇETİNKAYA A., GÖÇMEN R., KOŞUKCU C., Soylemezoglu F., ARSAVA E. M., et al.JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, cilt.30, sa.9, 2021 (SCI-Expanded, Scopus)
22. The evaluation of small fibers in asymptomatic carriers of Val30Met mutation: Results of three years follow-upBekircan-Kurt C. E., YILMAZ E., Aslan D., Yildiz F. G., DİKMETAŞ Ö., ERGÜL ÜLGER Z., et al.JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, cilt.26, sa.3, ss.379, 2021 (SCI-Expanded, Scopus)
23. Biologia Futura: the importance of 3D organoids-a new approach for research on neurological and rare diseasesAKBABA T. H., Bekircan-Kurt C. E., Balci-Peynircioglu B., Balci-Hayta B.BIOLOGIA FUTURA, cilt.72, sa.3, ss.281-290, 2021 (SCI-Expanded, Scopus)
24. A Rare Cause of Dystonia: Spinal MeningiomaSarayli A. A. K., Bekircan-Kurt C. E., GÖÇMEN R., ÖGE H. K., Tan E.TURKISH JOURNAL OF NEUROLOGY, cilt.27, sa.2, ss.215-216, 2021 (ESCI, Scopus, TRDizin)
25. Reliability and Validity of Turkish Myasthenia Gravis-Activities of Daily Living ScaleKARANFİL E., SALCI Y., FİL BALKAN A., Bekircan-Kurt C. E., ERDEM ÖZDAMAR S., ARMUTLU K.OTJR-OCCUPATION PARTICIPATION AND HEALTH, cilt.41, sa.2, ss.101-107, 2021 (SSCI, Scopus)
26. Psychosocial Adjustment and Adherence to Medication in Patients with Myasthenia GravisAŞİRET G. D., KAPUCU S., KAYMAZ T. T., Bekircan-Kurt C. E.GAZI MEDICAL JOURNAL, cilt.32, sa.3, ss.371-376, 2021 (ESCI, Scopus)
27. Organelle Positioning in Neurons and Skeletal Muscle CellsAKSU MENGEŞ E., KURAL MANGIT E., Bekircan-Kurt C. E., BORA G.GAZI MEDICAL JOURNAL, cilt.32, ss.341-347, 2021 (ESCI, Scopus)
28. Consistent improvement with eculizumab across muscle groups in myasthenia gravisMantegazza R., O'Brien F. L., Yountz M., Howard J. F., Gabriel Mazia C., Wilken M., et al.Annals of Clinical and Translational Neurology, cilt.7, sa.8, ss.1327-1339, 2020 (SCI-Expanded, Scopus)
29. Trigeminal sensory-motor neuropathy in a patient with mixed connective tissue disease and review of the literatureBekircan-Kurt C. E., TEMUÇİN Ç. M., APRAŞ BİLGEN Ş. Ş., ERDEM ÖZDAMAR S.NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, cilt.37, sa.3, ss.148-151, 2020 (SCI-Expanded, Scopus, TRDizin)
30. A Novel Amplification-Refractory Mutation System-PCR Strategy to Screen MT-TL1 Pathogenic Variants in Patient RepositoriesBulduk B. K., Kilic H. B., Bekircan-Kurt C. E., Haliloglu G., ERDEM ÖZDAMAR S., Topaloglu H., et al.GENETIC TESTING AND MOLECULAR BIOMARKERS, cilt.24, sa.3, ss.165-170, 2020 (SCI-Expanded, Scopus)
31. Giant cell myositis associated with myasthenia gravis and thymomaİNAN B., KURT C. E., Yildiz F. G., ERDEM ÖZDAMAR S., TEMUÇİN Ç. M., Tan E.NEUROLOGICAL SCIENCES AND NEUROPHYSIOLOGY, cilt.36, sa.4, ss.236-237, 2019 (SCI-Expanded, Scopus, TRDizin)
32. Long-term safety and efficacy of eculizumab in generalized myasthenia gravisMuppidi S., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., et al.Muscle and Nerve, cilt.60, sa.1, ss.14-24, 2019 (SCI-Expanded, Scopus)
33. Laboratory diagnosis of metachromatic leukodystrophy requires more than arylsulfatase A assayPekgul F., Bekircan-Kurt C. E., Konuskan B., Erdem-Ozdamar S., Tan E., Akarsu N., et al.FEBS OPEN BIO, cilt.9, ss.199, 2019 (SCI-Expanded, Scopus)
34. Two sisters with anti-MuSK-positive myasthenia gravisKURT E., Bekircan-Kurt C. E., KONUŞKAN B., ERKENT ERCAN İ., Tan E., Anlar B.CLINICAL NEUROLOGY AND NEUROSURGERY, cilt.182, ss.17-18, 2019 (SCI-Expanded, Scopus)
35. Establishment of primary myoblast cell cultures from cryopreserved skeletal muscle biopsies to serve as a tool in related research & development studiesBalci-Hayta B., Bekircan-Kurt C. E., AKSU MENGEŞ E., DAYANGAÇ ERDEN D., Tan E., ERDEM ÖZDAMAR S.JOURNAL OF THE NEUROLOGICAL SCIENCES, cilt.393, ss.100-104, 2018 (SCI-Expanded, Scopus)
36. Ocular surface alterations and in vivo confocal microscopic characteristics of corneas in patients with myasthenia gravisERKAN TURAN K., KOCABEYOĞLU S., Bekircan-Kurt C. E., BEZCİ F., ERDEM ÖZDAMAR S., Irkec M.EUROPEAN JOURNAL OF OPHTHALMOLOGY, cilt.28, sa.5, ss.541-546, 2018 (SCI-Expanded, Scopus)
37. The histopathological evaluation of small fiber neuropathy in patients with vitamin B12 deficiencyGunes H. N., Bekircan-Kurt C. E., Tan E., ERDEM ÖZDAMAR S.ACTA NEUROLOGICA BELGICA, cilt.118, sa.3, ss.405-410, 2018 (SCI-Expanded, Scopus)
38. ERLIN1 mutations cause teenage-onset slowly progressive ALS in a large Turkish pedigreeTunca C., Akcimen F., Coskun C., Gundogdu-Eken A., Kocoglu C., ÇEVİK B., et al.EUROPEAN JOURNAL OF HUMAN GENETICS, cilt.26, sa.5, ss.745-748, 2018 (SCI-Expanded, Scopus)
39. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyHoward J. F., Utsugisawa K., Benatar M., Murai H., Barohn R. J., Illa I., et al.The Lancet Neurology, cilt.16, sa.12, ss.976-986, 2017 (SCI-Expanded, Scopus)
40. Myophosphorylase (PYGM) mutations determined by next generation sequencing in a cohort from Turkey with McArdle diseaseInal-Gultekin G., Toptas-Hekimoglu B., Gormez Z., Gelisin O., Durmus H., Erguner B., et al.NEUROMUSCULAR DISORDERS, cilt.27, sa.11, ss.997-1008, 2017 (SCI-Expanded, Scopus)
41. CELLULAR INFILTRATES IN SKIN AND SURAL NERVE OF PATIENTS WITH POLYNEUROPATHIESUeceyler N., Braunsdorf S., Kunze E., Riediger N., Scheytt S., Divisova S., et al.MUSCLE & NERVE, cilt.55, sa.6, ss.884-893, 2017 (SCI-Expanded, Scopus)
42. New mutations and genotype-phenotype correlation in late-onset Pompe patientsBekircan-Kurt C. E., Gunes H. N., Yildiz F. G., SAKA TOPÇUOĞLU E., Tan E., ERDEM ÖZDAMAR S.ACTA NEUROLOGICA BELGICA, cilt.117, sa.1, ss.269-275, 2017 (SCI-Expanded, Scopus)
43. Single-pulse Transcranial Magnetic Stimulation in Amyotrophic Lateral Sclerosis: Experience of a single institutionYildiz F. G., Bekircan-Kurt C. E., VARLI K.JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, cilt.34, sa.1, ss.70-75, 2017 (SCI-Expanded, Scopus, TRDizin)
44. Dysferlinopathy: A Case Report and Literature UpdateKutlu O., KURT C. E., Unsal I., Aribas Z., Renkliyildiz B., Eruzun H., et al.ISTANBUL MEDICAL JOURNAL, cilt.17, sa.4, ss.136-140, 2016 (ESCI, TRDizin)
45. Autoimmune stormAslan S., Bekircan-Kurt C. E., Kurne A. T., Erdem-Ozdamar S.EUROPEAN JOURNAL OF NEUROLOGY, cilt.23, ss.437, 2016 (SCI-Expanded, Scopus)
46. The evaluation of small fibres in asymptomatic patients with Val30Met mutationBekircan-Kurt C. E., Yildiz F. G., Gunes H. N., Erdem-Ozdamar S., Tan E.EUROPEAN JOURNAL OF NEUROLOGY, cilt.23, ss.231, 2016 (SCI-Expanded, Scopus)
47. Spinal muscular atrophy type III: Molecular genetic characterization of Turkish patientsBORA-TATAR G., YESBEK-KAYMAZ A., BEKIRCAN-KURT C. E., ERDEM-OZDAMAR S., Erdem-Yurter H.EUROPEAN JOURNAL OF MEDICAL GENETICS, cilt.58, sa.12, ss.654-658, 2015 (SCI-Expanded, Scopus)
48. The Activation of RAGE and NF-KB in Nerve Biopsies of Patients with Axonal and Vasculitic NeuropathyBekircan-Kurt C. E., TAN E., OZDAMAR S. E.NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.52, sa.3, ss.279-282, 2015 (SCI-Expanded, Scopus, TRDizin)
49. Three Turkish families with different transthyretin mutationsBekirean-Kurt C. E., GUNES N., Yilmaz A., ERDEM-OZDAMAR S., TAN E.NEUROMUSCULAR DISORDERS, cilt.25, sa.9, ss.686-692, 2015 (SCI-Expanded, Scopus)
50. Voltage gated calcium channel antibody-related neurological diseases.Bekircan-Kurt C. E., Derle Ç., KURNE A., ANLAR B.World journal of clinical cases, cilt.3, ss.293-300, 2015 (SCI-Expanded, Scopus)
51. CUTANEOUS ACTIVATION OF RAGE IN NONSYSTEMIC VASCULITIC AND DIABETIC NEUROPATHYBekircan-Kurt C. E., Ueceyler N., SOMMER C.MUSCLE & NERVE, cilt.50, sa.3, ss.377-383, 2014 (SCI-Expanded, Scopus)
52. The Course of Myasthenia Gravis with Systemic Lupus ErythematosusBekircan-Kurt C. E., Kurne A. T., Erdem-Ozdamar S., Kalyoncu U., Karabudak R., Tan E.EUROPEAN NEUROLOGY, cilt.72, ss.326-329, 2014 (SCI-Expanded, Scopus)
53. Myasthenia Gravis; Single Entity, Variable Clinical Features: Ten Years of Clinical Experience in a Tertiary Care Center Ten Years Clinical Experience of a Tertiary Care CenterBEKIRCAN-KURT C. E., KURNE A., ERDEM ÖZDAMAR S., KARABUDAK R., KANSU T., TAN E.JOURNAL OF NEUROLOGICAL SCIENCES-TURKISH, cilt.30, sa.1, ss.135-143, 2013 (SCI-Expanded, Scopus, TRDizin)
54. 'Jaw clenching' in anti-Ri - Antibody-associated paraneoplastic syndromeBekircan-Kurt C. E., TEMUÇİN Ç. M., ELİBOL B., SAKA E.PARKINSONISM & RELATED DISORDERS, cilt.19, sa.1, ss.132-133, 2013 (SCI-Expanded, Scopus)

1. The effect and challenges of nusinersen treatment in adult spinal muscular atrophy patients - preliminary resultsInan B., Bekircan-Kurt C. E., Kilinc M., Erdem-Ozdamar S., Tan E.6th Congress of the European-Academy-of-Neurology (EAN), ELECTR NETWORK, 23 - 26 Mayıs 2020, cilt.27, ss.625, (Özet Bildiri)
2. Multimodal Assessment Of Intensive Care Unit-Acquired Weakness (ICU-AW) In Severe Acute Stroke PatientsİNAN B., KURT C. E., TEMUÇİN Ç. M., ARSAVA E. M., TOPÇUOĞLU M. A., ERDEM ÖZDAMAR S., et al.2019 PNS Meeting, 22 - 26 Haziran 2019, (Özet Bildiri)
3. Erişkin Kas Hastalarında Fiziksel Aktiviteyi Objektif ve Subjektif Olarak Değerlendiren Yöntemlerin KarşılaştırılmasıAYVAT F., AYVAT E., ONURSAL KILINÇ Ö., SÜTÇÜ G., DOĞAN M., KILINÇ M., et al.TND II. Nöromusküler Hastalıklar Kongresi, İzmir, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
4. Nusinersen İlacı İçin Başvuruda Bulunan Spinal Musküler Atrofi Tip 2 ve Tip 3 Tanılı Hastaların ProfiliONURSAL KILINÇ Ö., AYVAT F., SÜTÇÜ G., DOĞAN M., AYVAT E., KILINÇ M., et al.TND II. Nöromusküler Hastalıklar Kongresi, İzmir, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
5. Erişkin Nöromusküler Hastalarda Düşme Öyküsünün AktiviteLimitasyonu ve Gövde Bozukluk Düzeyi ile İlişkisinin İncelenmesiDOĞAN M., ONURSAL KILINÇ Ö., AYVAT F., SÜTÇÜ G., AYVAT E., KILINÇ M., et al.TND II. Nöromusküler Hastalıklar Kongresi, İzmir, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
6. Erişkin Kas Hastalarında Fiziksel Aktivite ile İlişkili Faktörlerin BelirlenmesiAYVAT F., AYVAT E., ONURSAL KILINÇ Ö., SÜTÇÜ G., DOĞAN M., KILINÇ M., et al.TND II. Nöromusküler Hastalıklar Kongresi, İzmir, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
7. Kas Hastalarında Farklı Yüksekliklerden Oturmadan Ayağa Kalkma Sırasında Uyluk Kaslarının Aktivasyon Seviyelerinin İncelenmesiSÜTÇÜ G., DOĞAN M., ONURSAL KILINÇ Ö., AYVAT F., AYVAT E., AKSU YILDIRIM S., et al.TND II. Nöromusküler Hastalıklar Kongresi, İzmir, Türkiye, 19 - 21 Nisan 2019, (Özet Bildiri)
8. Nöroloji Yoğun Bakım Ünitesi'ndeki İnme Hastalarında Yoğun Bakım Ünitesinde Edinilmiş Güçsüzlüğün (YBÜ-EG) Multimodal İncelemesiİNAN B., KURT C. E., ERDEM ÖZDAMAR S., ARSAVA E. M., TOPÇUOĞLU M. A., TAN M. E., et al.35. ULUSAL KLİNİK NÖROFİZYOLOJİ EEG-EMG KONGRESİ, Muğla, Türkiye, 3 - 07 Nisan 2019, (Özet Bildiri)
9. Differentially Expressed microRNA Profile in Skeletal Muscle Tissue of Sporadic ALS PatientsBekircan-Kurt C. E., AKSU MENGEŞ E., Balci-Hayta B., Aydinoglu A. T., Erdem-Ozdamar S., Tan E.71st Annual Meeting of the American-Academy-of-Neurology (AAN), Pennsylvania, Amerika Birleşik Devletleri, 4 - 10 Mayıs 2019, cilt.92, (Özet Bildiri)
10. The expression of epidermal growth factor (EGF) and keratinocyte growth factor (KGF) in skin biopsy of amyotrophic lateral sclerosis patientsKURT E., Bekircan-Kurt C. E., ERDEM ÖZDAMAR S., Tan E.70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los-Angeles, Şili, 21 - 27 Nisan 2018, cilt.90, (Özet Bildiri)
11. Myastenia gravis hastalarında altı dakika yürüyüş testinin kullanımıSALCI Y., KARANFİL E., ÇALIK KÜTÜKCÜ E., FİL BALKAN A., CEREN A. N., AYVAT F., et al.1. Kardiyopulmoner Rehabilitasyon Kongresi, Türkiye, 22 - 25 Kasım 2017, cilt.29, (Özet Bildiri)
12. Myastenia gravisli bireylerde fizisel kapasitenin solunum fonksiyonları, yaşam kalitesi ve özür seviyesi ile ilişkisiKARANFİL E., CEREN A. N., SALCI Y., FİL BALKAN A., ÇALIK KÜTÜKCÜ E., AYVAT F., et al.53. Ulusal Nöroloji Kongresi, Türkiye, 24 - 30 Kasım 2017, (Özet Bildiri)
13. Myastenia gravis hastalarının hastalığa psikososyal uyumu ve ilaç uyumlarının belirlenmesi.DURU AŞİRET G., KAPUCU S., TÜRTEN KAYMAZ T., KURT C. E.. 5. Uluslararası, 16. Ulusal Hemşirelik Kongresi, Ankara, Türkiye, 5 - 08 Kasım 2017, (Özet Bildiri)
14. VECTOR-BORNE VIRAL INFECTIONS IN GUILLAIN BARRE SYNDROME PATIENTSOkar S., ERGÜNAY K., Bekircan-Kurt C. E., Erdem-Ozdamar S., Tan E.Peripheral-Nerve-Society Meeting, Sitges, İspanya, 8 - 12 Temmuz 2017, cilt.22, ss.349-350, (Özet Bildiri)
15. Acute myopathy in patients who are using short-term and low-dose systemic glucucorticoids: Preliminary findingsİLBAY A., DURUSU TANRIÖVER M., KURT C. E., YILDIZ SARIKAYA F. G., ÖZIŞIK L., ERDEM ÖZDAMAR S.16th European Congress of Internal Medicine, 31 Ağustos - 02 Eylül 2017, (Özet Bildiri)
16. Recurrent peripheral and central demyelination in a seronegative patientKURT C. E., YILDIZ SARIKAYA F. G., TEMUÇİN Ç. M., TUNCER M. A., TAN M. E., ERDEM ÖZDAMAR S.peripheral Nerve Society Meeting, 8 Temmuz - 13 Eylül 2017, (Özet Bildiri)
17. Low levels of SMN cause alterations in microtubule associated protein 1bBORA G., Rademacher S., YEŞBEK KAYMAZ A., Hensel N., KURT C. E., ERDEM ÖZDAMAR S., et al.21th Annual Spinal Muscular Atrophy Researcher Meeting, Orlando, Amerika Birleşik Devletleri, 29 Haziran - 02 Temmuz 2017, (Özet Bildiri)
18. The Histopathological Evaluation of Small Fiber Neuropathy in Patients with Vitamin B12 DeficiencyBekircan-Kurt C. E., Gunes N., DEMİRCİ M., ERDEM ÖZDAMAR S., Tan E.68th Annual Meeting of the American-Academy-of-Neurology (AAN), Vancouver, Kanada, 15 - 21 Nisan 2016, cilt.86, (Özet Bildiri)
19. Myastenia Gravis de Velofaringeal Fonksiyonun AraştırılmasıBAŞTUĞ A., KULAK KAYIKCI M. E., KUŞCU O., KURT C. E., ERDEM ÖZDAMAR S.4. YUTMA BOZUKLUKLARI KONGRESİ, Türkiye, 19 - 21 Kasım 2015, (Özet Bildiri)
20. A RARE CAUSE OF LUMBOSACRAL PLEXOPATHY: BLADDER DIVERTICULUMKAYA A., Bekircan-Kurt C. E., GOCMEN R., TAN E.Biennial Meeting of the Peripheral-Nerve-Society, Quebec, Kanada, 27 Haziran - 02 Temmuz 2015, cilt.20, ss.166-167, (Özet Bildiri)
21. A HEREDITARY AMYLOID POLYNEUROPATHY FAMILY DUE TO VAL30MET MUTATION WITH AN INDEX CASE PRESENTED LIKE CIDPBekircan-Kurt C. E., ERDEM-OZDAMAR S., TAN E.Biennial Meeting of the Peripheral-Nerve-Society, Quebec, Kanada, 27 Haziran - 02 Temmuz 2015, cilt.20, ss.103, (Özet Bildiri)
22. A novel mutation in the HTRA1 gene in a Turkish family with CARASILBekircan-Kurt C. E., KOŞUKCU C., KURNE A. T., TOPÇUOĞLU M. A., ERDEM-OZDAMAR S., GÖÇMEN R., et al.1st Congress of the European-Academy-of-Neurology, Berlin, Almanya, 20 - 23 Haziran 2015, cilt.22, ss.258, (Özet Bildiri)
23. The incidence of Pompe disease in patients with vacuolar myopathy: a pilot study of a tertiary care centerBekircan-Kurt C. E., GUNES H. N., ERDEM-OZDAMAR S., TAN E.1st Congress of the European-Academy-of-Neurology, Berlin, Almanya, 20 - 23 Haziran 2015, cilt.22, ss.623, (Özet Bildiri)
24. The time course of pseudo-conduction blocks in a patient with vasculitic neuropathyBekircan-Kurt C. E., KALYONCU U., ERDEM-OZDAMAR S., TEMUÇİN Ç. M.Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.261, (Özet Bildiri)
25. Three families with hereditary amyloid polyneuropathy with three different mutationsBekircan-Kurt C. E., GUNES N., Yilmaz A., ERDEM-OZDAMAR S., TAN E.Joint Congress of European Neurology, İstanbul, Türkiye, 31 Mayıs - 03 Haziran 2014, cilt.261, (Özet Bildiri)
26. NUSİNERSEN TEDAVİSİ ALAN ERİŞKİN SPİNAL MUSKÜLER ATROFİ HASTALARINDA İNFLAMASYON VE GLİAL HÜCRE İLİŞKİLİ BİYOBELİRTEÇLERİN TESPİTİARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.
27. MİYASTENİK KRİZ İLE BAŞVURAN HASTALARDA YARDIMCI FOLİKÜLER T HÜCRE (TFH) VE YARDIMCI T HÜCRE 17 (TH17) İLİŞKİLİ SİTOKİNLERİN TEDAVİ ÖNCESİ VE SONRASI DEĞİŞKENLİĞİARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.
28. Evaluation of the Role of Glial Factors in the Pathogenesis of Spinal Muscular AtrophyARSLAN D., ERGÜL ÜLGER Z., gökşen s., İNAN B., ESENDAĞLI G., ERDEM ÖZDAMAR S., et al.
29. Serum Cytokines Levels in Patients with Myasthenia Gravis and Their Changes After TreatmentARSLAN D., ERGÜL ÜLGER Z., gökşen s., ESENDAĞLI G., ERDEM ÖZDAMAR S., TAN M. E., et al.
30. MME MUTASYONUNA BAĞLI DEMİYELİNİZAN NÖROPATİDemirel Özbek E., ERGÜL ÜLGER Z., TAN M. E., ERDEM ÖZDAMAR S., KURT C. E.
31. The evaluation of small fibers in asymptomatic carriers of Val30Met mutation: Results of three years follow-upKURT C. E., YILMAZ E., aslan d., YILDIZ SARIKAYA F. G., DİKMETAŞ Ö., ERGÜL ÜLGER Z., et al.
32. Multimodal Assessment of Intensive Care Unit- Acquired Weakness in Severe Stroke PatientsİNAN B., KURT C. E., ERGÜL ÜLGER Z., yılmaz m.